Olema Pharmaceuticals
OLMA
130 hedge funds and large institutions have $700M invested in Olema Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 17 closing their positions.
905% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $286K
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
12% more capital invested
Capital invested by funds: $626M → $700M (+$73.9M)
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 128 → 130 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.09% less ownership
Funds ownership: 103.52% → 102.42% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
+$21.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.07M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.41M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$30.7M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.8M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$4.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.94M |
OLMA Hedge Fund Activity: Q3 2024 in Review
130 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2024, worth a combined $700M — up 12% from $626M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OLMA positions and 17 closed out — a net gain of 2 holders — while 47 added to existing stakes and 42 trimmed.
The largest buyer was Pictet Asset Management, opening a new position worth an estimated $21.3M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $30.7M.
- 130 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2024, up from 128 in Q2 2024.
- Funds reported $700M of Olema Pharmaceuticals stock for Q3 2024, up 12% quarter-over-quarter.
- 19 funds opened new Olema Pharmaceuticals positions in Q3 2024 and 17 closed out, a net change of +2 holders.
- The largest Olema Pharmaceuticals buyer in Q3 2024 was Pictet Asset Management, an estimated $21.3M added.
- The largest Olema Pharmaceuticals seller in Q3 2024 was Paradigm Biocapital Advisors, an estimated $30.7M sold.
Based on aggregated 13F filings for Q3 2024.